MedTrace Logo

Tranexamic Acid Dosing for Total Joint Arthroplasty

NCT02584725 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of increasing doses of tranexamic acid (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a change in hemoglobin from pre-operative baseline to the first post-operative day.

Conditions

  • Arthropathy of Hip
  • Arthropathy of Knee

Interventions

DRUG

Tranexamic Acid

Comparison of 3 different doses of the drug

Sponsors & Collaborators

Principal Investigators

  • Robert Maniker, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584725 on ClinicalTrials.gov